Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olodanrigan - Novartis

Drug Profile

Olodanrigan - Novartis

Alternative Names: EMA-401

Latest Information Update: 18 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spinifex Pharmaceuticals
  • Developer Novartis
  • Class Analgesics; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Angiotensin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 10 Apr 2019 Novartis terminates the phase-II EMPHENE trial in Post-herpetic Neuralgia (Treatment-experienced) in Australia, Austrial, Belgium, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, South Korea, Norway, Poland, Portugal, Slovakia, Taiwan, United Kingdom, Spain (PO) (NCT03094195)
  • 15 Mar 2019 Novartis terminates the phase-II EMPADINE trial in Diabetic neuropathies (In adults, In the elderly) in Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Germany, Finland, France, Hungary, Norway, Poland, Portugal, Spain, Slovakia, United Kingdom due to safety reasons (NCT03297294)
  • 31 Dec 2018 Novartis announces intention to submit regulatory applications for Neuropathic pain in 2023 (Novartis pipeline, March 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top